AR104934A1 - Moduladores de receptores nucleares - Google Patents

Moduladores de receptores nucleares

Info

Publication number
AR104934A1
AR104934A1 ARP160101700A ARP160101700A AR104934A1 AR 104934 A1 AR104934 A1 AR 104934A1 AR P160101700 A ARP160101700 A AR P160101700A AR P160101700 A ARP160101700 A AR P160101700A AR 104934 A1 AR104934 A1 AR 104934A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally substituted
independently
cycloalkyl
cra
Prior art date
Application number
ARP160101700A
Other languages
English (en)
Inventor
E Kort Michael
Mounier Laurent
Poupardin Olivia
Amaudrut Jerome
Barth Martine
Potin Dominique
C Hobson Adrian
P Cusack Kevin
C Breinlinger Eric
A Argiriadi Maria
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of AR104934A1 publication Critical patent/AR104934A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Abstract

La presente solicitud se refiere a compuestos y sales farmacéuticamente aceptables de los mismos útiles para tratar trastornos inmunológicos. Reivindicación 1: Un compuesto caracterizado porque es de fórmula (1), una sal farmacéuticamente aceptable, o un estereoisómero del mismo, donde W es C o CRᵃ, L¹ está conectado a W o Y; y A y E son en forma independiente C o N con la condición de que no son ambos N; V es CR³ o N; X es CRᵃ, NRᵃ, N, ó O; Y es C, CRᵃ, NRᵃ, N, O ó S; Z es CR³ o N; o W es N o NRᵃ, L¹ está conectado a W o Y; y A y E son en forma independiente C o N con la condición de que no son ambos N; V es CR³ o N; X es CRᵃ, NRᵃ, o N; Y es C, CRᵃ, o N; Z es CR³ o N; o Cy es un anillo aromático, heteroaromático o parcialmente saturado de seis miembros sustituido con R¹ y R²; L¹ es -CH(Rᵇ)-, -C(Rᵇ)(Rᵈ)-, -C(O)- o -N(Rᶜ)-; L² es -C(O)-, -O-, -C(Rᵇ)(Rᵈ)-, -S-, -S(O)-, -S(O)₂-; R¹ y R² son en forma independiente halo, -O-C₁₋₃ alquilo, -O-C₃₋₆ cicloalquilo, C₃₋₆ cicloalquilo opcionalmente sustituido, o -C₁₋₃ alquilo; cada R³ es en forma independiente H, CF₃, CN, halo, -C(=O)C₁₋₃ alquilo, -C(O)N(Rᵉ)₂, -NRᵉCORᵉ, -OCHF₂, OCF₃, -O-C₁₋₃ alquilo, -O-C₃₋₆ cicloalquilo, -S-C₁₋₃ alquilo, C₁₋₆ alquilo opcionalmente sustituido, C₃₋₆ cicloalquilo opcionalmente sustituido, heteroarilo opcionalmente sustituido o heterociclo opcionalmente sustituido; R⁴ es H, -OH, C₁₋₆ alquilo opcionalmente sustituido, -NR⁵R⁶, C₃₋₆ cicloalquilo opcionalmente sustituido o -(CH₂)ₘ-heterociclo opcionalmente sustituido; donde R⁵ es H o -C₁₋₃ alquilo, y R⁶ es C₁₋₄ alquilo opcionalmente sustituido, C₃₋₆ cicloalquilo opcionalmente sustituido o -(CH₂)ₘ-heterociclo opcionalmente sustituido; o R⁵ y R⁶, junto con el átomo de nitrógeno al que están unidos, forman un heterociclo opcionalmente sustituido; cada Rᵃ es en forma independiente H, -C(O)CH₃, C₁₋₆ alquilo opcionalmente sustituido, C₃₋₆ cicloalquilo opcionalmente sustituido o -S(O)₂-fenilo; cada Rᵇ es en forma independiente H, F, OH, -O-C₁₋₃ alquilo, o C₁₋₃ alquilo; Rᶜ es en forma independiente H o -C₁₋₃ alquilo; cada Rᵈ es en forma independiente H, F, o C₁₋₃ alquilo; o Rᵈ y Rᵇ forman un C₃₋₅ espirociclo; Rᵉ es en forma independiente H o -C₁₋₃ alquilo; y m es en forma independiente 0 ó 1; con la condición de que no más que dos de A, E, W, X e Y son N.
ARP160101700A 2015-06-09 2016-06-08 Moduladores de receptores nucleares AR104934A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2015/001693 WO2016198908A1 (en) 2015-06-09 2015-06-09 Ror nuclear receptor modulators

Publications (1)

Publication Number Publication Date
AR104934A1 true AR104934A1 (es) 2017-08-23

Family

ID=54293273

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101700A AR104934A1 (es) 2015-06-09 2016-06-08 Moduladores de receptores nucleares

Country Status (3)

Country Link
AR (1) AR104934A1 (es)
PE (1) PE20181020A1 (es)
WO (1) WO2016198908A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108689942B (zh) * 2017-04-11 2023-06-09 广东东阳光药业有限公司 含氮双环化合物及其制备方法和用途
US11427596B2 (en) * 2019-07-19 2022-08-30 Indian Institute of Technology Indore Metal-free solvent-free synthesis of fused-pyrido heterocycles and biomedical applications
IL293592A (en) 2019-12-06 2022-08-01 Vertex Pharma Transduced tetrahydrofurans as sodium channel modulators
US20230183245A1 (en) 2020-04-06 2023-06-15 Basf Se Imidazo-pyrimidone compounds as pesticides
EP4347031A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070129334A1 (en) 2001-10-30 2007-06-07 Conforma Therapeutics Corporation Orally Active Purine-Based Inhibitors of Heat Shock Protein 90
EP1465882B1 (en) 2001-12-21 2011-08-24 X-Ceptor Therapeutics, Inc. Hetrocyclic modulators of nuclear receptors
AU2003297431A1 (en) 2002-12-20 2004-07-22 Pharmacia Corporation Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds
US7312215B2 (en) 2003-07-29 2007-12-25 Bristol-Myers Squibb Company Benzimidazole C-2 heterocycles as kinase inhibitors
UY28526A1 (es) 2003-09-24 2005-04-29 Boehringer Ingelheim Pharma Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
WO2006012093A1 (en) 2004-06-24 2006-02-02 Eli Lilly And Company Compounds and methods for treating dyslipidemia
PL1807072T3 (pl) 2004-10-29 2009-06-30 Lilly Co Eli Cykloalkilowe pochodne laktamów jako inhibitory 11-ß-HSD1
US7855205B2 (en) 2004-10-29 2010-12-21 Janssen Pharmaceutica Nv Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
US8026257B2 (en) 2007-07-11 2011-09-27 Bristol-Myers Squibb Company Substituted heterocyclic ethers and their use in CNS disorders
MX2011008276A (es) 2009-02-06 2011-12-14 Elan Pharm Inc Inhibidores de quinasa jun n-terminal.
NZ598269A (en) 2009-09-18 2014-12-24 Zalicus Pharmaceuticals Ltd Aryl sulphone derivatives as calcium channel blockers
US8466186B2 (en) * 2010-12-10 2013-06-18 Boehringer Ingelheim International Gmbh Compounds
EP2487159A1 (en) * 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
US8513419B2 (en) 2011-07-25 2013-08-20 Allergan, Inc. N-(imidazolidin-2-ylidene)-heterocyclopenta[b]pyridine derivatives as modulators of alpha 2 adrenergic receptors
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
KR20140077963A (ko) 2011-10-20 2014-06-24 글락소스미스클라인 엘엘씨 시르투인 조절제로서의 치환된 비시클릭 아자-헤테로사이클 및 유사체
EP2647628A1 (en) 2012-04-02 2013-10-09 Almirall, S.A. Substituted tricyclic compounds with activity towards ep1 receptors
WO2014026328A1 (en) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof
CN105531274A (zh) * 2013-09-11 2016-04-27 豪夫迈·罗氏有限公司 作为RORc调节剂的酮-咪唑并吡啶衍生物

Also Published As

Publication number Publication date
PE20181020A1 (es) 2018-06-27
WO2016198908A1 (en) 2016-12-15

Similar Documents

Publication Publication Date Title
AR104934A1 (es) Moduladores de receptores nucleares
AR099177A1 (es) Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
AR094668A1 (es) Amidas como moduladores de canales de sodio
AR102361A1 (es) Compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2
AR089865A1 (es) Derivados de bencimidazol e imidazopiridinas como moduladores de canales de sodio
AR106865A1 (es) Piridinas sustituidas y métodos de uso
AR104362A1 (es) Dihidropiridoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios
AR096684A1 (es) Compuestos para tratar atrofia muscular espinal
AR092270A1 (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
AR098522A1 (es) Compuesto de triazolo-piridina
AR103598A1 (es) Ácidos bicíclicos[4,6,0]hidroxámicos como inhibidores de hdac
AR091939A1 (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
AR107010A1 (es) Derivados de piperidina puenteados
AR104880A1 (es) MODULADORES DE ROR GAMMA (RORg)
AR104306A1 (es) Tetralinas de ácido 3-espiro-7-hidroxámico como inhibidores de hdac
AR101359A1 (es) Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo
AR095359A1 (es) Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina
AR110001A1 (es) Derivados heteroarilo bicíclicos
AR104293A1 (es) Indazolonas como moduladores de la señalización de tnf
AR109950A1 (es) INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
AR101696A1 (es) Compuestos de azetidiniloxifenilpirrolidina
AR106185A1 (es) Compuestos macrocíclicos de sulfondiimina
AR097739A1 (es) Imidazo[1,2-a]piridina-7-aminas
AR109108A1 (es) Derivados de aminopiridina y su uso como inhibidores selectivos de alk-2
AR093128A1 (es) Inhibidores de la syk